David Ilson
机构: Professor of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center
每年引用次数
引用次数
引用: 20,200
H-指数: 72
I10-指数 : 212
出版物: 482
Toxicity of chemotherapy for esophageal carcinoma.
Ilson D
Chest Surgery Clinics of North America 7 ( 3) 551
3
1997
Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site.
R. S. K. Chaganti , D. H. Ilson , R. J. Motzer , E. Rodriguez
Seminars in Oncology 20 ( 3) 229 -237
32
1993
Paclitaxel in the treatment of carcinoma of the esophagus.
J. A. Ajani , D. P. Kelsen , K. Daugherty , D. H. Ilson
Seminars in Oncology 22 ( 3) 35 -40
26
1995
Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas
Jaffer A Ajani , D. P. Kelsen , D. H. Ilson
Seminars in Oncology 23 ( 5) 55 -58
14
1996
The activity of paclitaxel in gastrointestinal tumors
J. A. Ajani , D. P. Kelsen , D. H. Ilson
Seminars in Oncology 22 ( 5) 46 -53
12
1995
Use of SUVmax to predict response to neoadjuvant chemoradiotherapy in patients with adenocarcinoma of the distal esophagus and GE Junction
N. P. Rizk , M. S. Bains , B. J. Park , R. M. Flores
Journal of Clinical Oncology 26 4565 -4565
1
2008
The association of PET response with complete pathological response (CPR) and residual nodal disease (RND) after induction chemoradiotherapy (CRT) and resection of esophageal cancer: A review of 493 cases
S. A. Barnett , N. P. Rizk , P. S. Adusumilli , B. J. Park
Journal of Clinical Oncology 27 4552 -4552
2009
Taxol-Induced Soft-Tissue Injury Secondary to Extravasation: Characterization by Histopathology and Clinical Course
J. A. Ajani , L. G. Dodd , K. Daugherty , D. Warkentin
Journal of the National Cancer Institute 86 ( 1) 51 -53
41
1994
Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus
J. A. Ajani , D. H. Ilson , K. Daugherty , R. Pazdur
Journal of the National Cancer Institute 86 ( 14) 1086 -1091
220
1994
Diabetes mellitus (DM), serum glucose, and outcome in gastroesophageal (GE) cancer
J. W. Feilchenfeldt , M. Capanu , A. Farooki , D. Sully
Journal of Clinical Oncology 27 ( 15_suppl) e15661 -e15661
2009
The AJCC staging system does not predict survival in patients receiving multimodality therapy for esophageal cancer
N. P. Rizk , M. S. Bains , D. H. Ilson , B. Minsky
Journal of Clinical Oncology 23 ( 16_suppl) 4005 -4005
7
2005
Outcomes of induction chemotherapy followed by chemoradiation using intensity‐modulated radiation therapy for esophageal adenocarcinoma
N. Gerber , D. H. Ilson , A. J. Wu , Y. Y. Janjigian
Diseases of The Esophagus 27 ( 3) 235 -241
7
2014
Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
D. Molena , H. H. Sun , A. S. Badr , B. Mungo
Diseases of The Esophagus 27 ( 4) 355 -359
23
2014
Phase II trial of preoperative cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy: PET scan after induction therapy may identify early treatment failure
D. H. Ilson , M. Bains , N. Rizk , M. Shah
Journal of Clinical Oncology 24 ( 18_suppl) 4023 -4023
8
2006
Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer
G. Y. Ku , M. A. Shah , L. H. Tang , B. Miron
Journal of Clinical Oncology 26 15580 -15580
14
2008
Small cell carcinoma of the esophagus: Review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
G. Y. Ku , D. Kelsen , B. Minsky , V. Rusch
Journal of Clinical Oncology 25 ( 18_suppl) 4631 -4631
2007
OSI-774 in advanced esophageal cancer: a phase II study
D. Radovich , D. Kelsen , M. Shah , D. Klimstra
Journal of Clinical Oncology 22 4077 -4077
5
2004
Combined modality therapy in the treatment of esophageal cancer.
Ilson Dh , Kelsen Dp
Seminars in Oncology 21 ( 4) 493 -507
63
1994
Adjuvant postoperative therapy of gastrointestinal malignancies.
Ilson Dh , Kelsen Dp
Oncology 8 ( 7) 75
4
1994
Cisplatin and irinotecan in upper gastrointestinal malignancies.
Ilson Dh , O'Reilly Em
Oncology 15 42
5
2001